IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN THE UNITED STATES PATENT AN	ID (KADEIIII	48
Aug. Det : Cl 0012	207	207
Assistant Commissioner for Patents Washington, D.C. 20231 jc772 U.S. PTO Date: March 30, 1		10928 U
Sir: 03/30/01-20		4
Attached for filing is the patent application of:	INS,	_
Entitled: ISOLATED HUMAN DRUG-METABOLIZING PROTEINS, METABOLIZING PROTEINS,	ORUG-	,
AND USES THEREOF and including attachments as noted below: Abstract Abstract Abstract	ding 23 numbered claims), and	
	ned	nt of
	ne following foreign application: Day/Month/Year I Duntry	Filed
Application (Values)	- Lightion	, filed
respectively. Certified copy(ies) of foreign application(s) is/are attached to the first please amend the specification by inserting before the first please amend the specification by inserting before the first please amend the specification by inserting before the first plant of the specific please and the specific please and the specific please and the specific please are the specific please and the specific please are the specific please.	st lineThis is a of Forest state of the s	ating the U.S.,
, the entire desimed under 35 U.S.C 120/303 back	on the following prior to a pay/More rence in this application: Day/More country	nth/Year Filed
Application Number This application is based on the following prior provision Filing	nal application(s).	
This application is based on the following Filing Application No.	roference III IIIIs app.	rity is
Priority is hereby claimed the entire content of which is hereby incorporated by recomplication Number This application is based on the following prior provision Filing Application No. respectively, the entire content of which is hereby incorporated by recomplication No. respectively, the entire content of which is hereby incorporated by recomplication No. respectively, the entire content of which is hereby incorporated by recomplication No.	first line:This application claims the benefit of ire content of which is hereby incorporated by ref	U.S. ference in
m places amend the specification of stand the ent	ire content of white series (Rules 9 & 27)	Examiner for
this application.— trashed establishing "small entity"	ted in the parent application by applicant and the	
Verified Statement attached established to the prior art of the Examiner's attention is directed to the prior art of the reasons stated therein. The Examiner's attention is directed to the prior art of the reasons stated therein. The Examiner's attention is directed to the prior art of the pr	to be entered before calculation of the fee below	
the reasons stated therein.		\$ 710.00 \$ 54.00 \$ 240.00
	ΛΨ 1-1	\$ 0.00 \$ 1004.00
Total effective claims 6 - 3 (at least 3) - Independent claims 6 - 3 (at least 3) - Independent claims now added for first time	, add \$260.00 (ignore improper)	-\$(0.00 \$ 1004.00
If "small entity," then enter half (1/2) of subtotal and subtract	SECOND SUBTOTAL	\$ 0.00
Assignment Recording Fee (\$40.00)	TOTAL FEE CHARGED TO DEPOSIT ACCOUNT	should have been
Accidning in 1000. 5.1	the include a Deution for the control or which	SHOULD HOLD

Any future submission requiring an extension of time is hereby stated to include a petition for such time extension.

The Commissions is because at the state of Any ruture submission requiring an extension of time is nereby stated to include a petition for such time extension.

The Commissioner is hereby authorized to charge any <u>deficiency</u> in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our **Account No. 50-0970**. A <u>duplicate</u> copy of this sheet is attached sheet is attached.

CELERA Genomics Corporation 45 West Gude Drive, C2-4#20 Rockville, MD 20850 Telephone # 240-453-3067 LSH:pdc

CELERA GENOMICS Corporation By Atty: Lin Sun-Hoffman, Reg. No. 47,983

Signature:

Document13